Zhejiang Orient Gene Biotech (688298.CH) - Clearly Undervalued with Attractive Upside Potential
161 Views21 Jun 2021 09:18
This article mainly analyzed Zhejiang Orient Gene Biotech in terms of the industry characteristics, the business, the comparison with peers, the valuation, the key risks, and the upside potential.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
x